Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

FDA has approved colchicine tablets with a much lower dosing regimen for gout flares compared with historic dosing. The approval was accompanied by warnings for potential serious and life–threatening drug interactions if colchicine is coadministered with P–glycoprotein or strong cytochrome P450 (CYP)3A4 inhibitors.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address